High materiality7/10
Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Overweight rating reaffirmed; target $47; current price $16.15.
- Target $47; price $16.15.
Key facts
- 01
Target: $47
- 02
Posted price: $16.15
- 03
Analyst firm: Piper Sandler
- 04
Analyst: Edward Tenthoff
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.